Argenx Se · EURONEXT:ARGX
Argenx — J.P. Morgan Healthcare Conference January 2023
22 slides from Argenx's conference presentation, Jan 9, 2023
Slide 1: J.P. Morgan Healthcare Conference January 2023
J.P. Morgan Healthcare Conference January 2023
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation has been prepared by argenx se (“ argenx ” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presente
Slide 3: We are on a bold mission
We are on a bold mission Transforming the lives of patients with severe autoimmune disease through immunology i nnovation
Slide 4: Autoimmunity is Prime for Revolution
Autoimmunity is Prime for REVOLUTION A pipeline of precision tools Redefining Autoimmune Diseases With Precision Medicine Approach Redefine our pipeline of autoimmune diseases as IgG - mediated or complement - driven Offer new targeted treatment modality in diseases where innovation is most needed
Slide 5: Redefining What 'Well-Controlled' Means for the Patient
Redefining What ‘Well - Controlled’ Means for the Patient Achieve minimal symptom expression Reduce reliance on broad immunosuppressants Regain control of their lives, including professionally and socially Minimize treatment burden We want to transform gMG treatment for patients
Slide 6: argenx 2025: A Leading, Sustainable Immunology Company
Lead with Compassion for our Patients Drive Impact Through Innovation Pioneer with Our Science Build the Company We Want to Work For argenx 2025: A Leading, Sustainable Immunology Company …and gMG is just the beginning
Slide 7: 2022: Transformed into an Integrated Immunology Company
2022: Transformed into an Integrated Immunology Company VYVGART launched in U.S., Japan & Germany Enabled appropriate access through value - based agreements 90% US POLICIES FAVORABLE Built scalable global supply chain LARGE SCALE CAPACITY TO HANDLE DEMAND Rapid HCP adoption 90% of KEY TARGETS REACH
Slide 8: 2022: Strengthened Efgartigimod Data Story
2022: Strengthened Efgartigimod Data Story 0 - 30 - 60 Baseline 1 2 3 4 5 6 7 8 10 Mean I gG reduction % IgG reduction (%) in all ADAPT - SC and ADAPT participants LS - Mean Platelet Count Change From Baseline (x10 9 /L) - 20 0 20 40 0 12 24 Week VYVGART PLACEBO Clear Clinical Benefit in ITP Disease
Slide 9: 2022: Broadened Scope of Efgartigimod Safety Database
2022 : Broadened Scope of Efgartigimod Safety Database 1. Ulrichts P, et al. J Clin Invest . 2018;128(10):4372 - 4386. doi : 10.1172/JCI97911. Scope of Safety Database >1,300 clinical study subjects Molecular design yields unique interaction with FcRn and differentiated safety profile Post - marketi
Slide 10: 2023: Key Drivers of our Path to Profitability
Reach more patients with VYVGART globally Pioneer FcRn class of medicines Broaden immunology pipeline Build out innovation ecosystem commercial clinical clinical discovery 2023: Key Drivers of our Path to Profitability
Slide 11: Reach More Patients with VYVGART Globally
Reach More Patients with VYVGART Globally Geographic expansion Launch SC product offering Drive usage in earlier line patients Reach more patients with VYVGART globally commercial File for ITP in Japan Ongoing studies in new indications DRIVE GROWTH IN NEW PATIENT SEGMENTS DRIVE MULTI - DIMENSIONAL
Slide 12: IgG Autoantibodies Serve as Unifying Biology
IgG Autoantibodies Serve as Unifying Biology Rationale for POC Indications DSG - 1 DSG - 3 AChR GPIIb /IIIa NF155 Contactin1 BP180 BP230 JO - 1 SRP HMGCR Mi - 2 MPO - ANCA PR3 - ANCA PLA2R GPCR Immune complexes TSHR THSd7A NELL1 ANA Ro/SSA La/SSB Pioneer FcRn class of medicines clinical MuSK LRP4 DS
Slide 13: Pipeline-in-a-Product Indicates Significant Market Opportunity
Pipeline - in - a - Product Indicates Significant Market Opportunity PC - POTS > 500K ANCA 105K TED 10 0K Sjogren’s 330K Membranous Nephropathy 8 0K BP 52K gMG 65K ITP 57K Myositis 63K Pemphigus 19K CIDP 16K Lupus Nephritis 40 K AMR 8K clinical Patient numbers are U.S. prevalence from argenx market
Slide 14: Steady Cadence of Data Readouts Over Next Several Years
gMG 65K CIDP 16K BP* 52K Membranous Nephropathy 80K TED 100K ANCA 105K AMR 8K PC - POTS >500K Sjogren’s 330K Lupus Nephritis 40K Steady Cadence of Data Readouts Over Next Several Years APPROVED APPROVED/IN REVIEW 2023 DATA READOUTS 2023 DATA READOUTS 2024 DATA READOUTS 2024 DATA READOUTS 2025+ DATA
Slide 15: ARGX-117: Sweeping Antibody
Optimal recycling pH and Ca2 + switch No effector function ARGX - 117: Targets C2 at Junction of Classical and Lectin Pathways 2024 DATA READOUTS Three Indications Selected Based on Biology Rationale 2024 DATA READOUTS ARGX - 117: Sweeping Antibody Broaden immunology pipeline clinical Indication sel
Slide 16: ARGX-117: Strong Translational Biology Rationale for C2 Blockade in MMN
clinical ARGX - 117: Strong Translational Biology Rationale for C2 Blockade in MMN A - GM 1 antibody mediated complement attack on the Schwann cell membrane Significant disruption to the axo - glial junction and cytoplasmic paranodal loops resulting in conduction block – hall mark of MMN Campbell et
Slide 17: ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease
ARGX - 119: MuSK Agonist with Broad Potential in Neuromuscular Disease 10 dose cohorts 3 dose cohorts/4 weekly doses Congenital Myasthenic Syndrome (CMS) and MuSK MG First - in - Patient Single Ascending Dose (0.005mg/kg – 15mg/kg) Multiple Ascending Dose (0.3mg/kg – 2.5mg/kg) First - in - patient t
Slide 18: Positioned for Long-term Franchise Growth
Neuromuscular Neuromuscular Neuromuscular Neuromuscular Neuromuscular Neuromuscular Neuromuscular Neuromuscular Positioned for Long - term Franchise Growth Hematology and Rheumatology Neurology Dermatology Nephrology gMG , CIDP, Myositis, TED, MMN, CMS, Musk MG, ALS ITP, Sjogren’s, POTS, Anca Vascul
Slide 19: Innovation Ecosystem
Innovation Ecosystem Build out innovation ecosystem discovery
Slide 20: Positioned for a Catalyst-Rich 2023
Positioned for a Catalyst - Rich 2023 VYVGART gMG Approval in China VYVGART gMG Approval in Canada VYVGART gMG Launch in France, UK, Italy SC efgartigimod gMG Approval in US SC efgartigimod gMG Approval in EU SC efgartigimod gMG Submission in Japan VYVGART ITP Submission in Japan 2Q 2023 2H 2023 2H
Slide 21: Our mission continues…
Our mission continues… Humility Innovation Excellence Co - Creation Empowerment
Slide 22: Key: Breadth and Depth Within Autoimmune Pipeline
Program Indication Preclinical Phase 1 Proof of Concept Registrational Commercial VYVGART T gMG (IV) Efgartigimod gMG (SC) CIDP Myositis Thyroid Eye Disease ITP (IV) ITP (SC) COVID - 19 Mediated POTS Sjogren's Syndrome Anca Vasculitis Pemphigus Bullous Pemphigoid Membranous Nephropathy Lupus Nephrit
argenx — J.P. Morgan Healthcare Conference January 2023 on 6ix